The promise of in silico drug development to improve patient outcomes
In the last two years, pharmaceutical companies have become increasingly interested in the possibilities in silico technologies bring to the world’s multi-billion-dollar drug development market. Among the factors that have been reported as drivers of recent interest in what is also known as virtual clinical trials are the COVID-19-related restrictions that began impacting traditional human-based clinical trials in 2020.
In silico drug development utilizes real-world data (RWD), artificial intelligence (AI), computational …